Moreover, fully-adjusted models showed evidence of lower prostate cancer risk but not of lower PSA in nondrinkers as compared to drinkers in the first thirds of the distribution (OR 0.79, 95% CI: 0.64–0.99), but this effect was less pronounced in models 1 and 2 (Table 5). This evidence concerns the gene KLK3 and prostate cancer.